It’s not just weight that could be contributing to degenerative changes in obesity-related osteoarthritis. In this Q&A, Dr. Clifford J. Rosen, director of the Center for Clinical and Translational Research, Maine Medical Center Research Institute, Portland, discusses the mechanisms of osteoarthritis.
Interim results at 24 weeks show that 75.3% of patients treated with tildrakizumab achieved a 20% improvement compared to 50.6% with placebo.
In the phase 3b/4 ORAL Shift study, tofacitinib monotherapy was shown to be comparable to tofacitinib with methotrexate.
Three studies presented this weekend at EULAR in Madrid suggest that being overweight or obese can heighten the severity or arthritic disease.
The overall risk of cancer in psoriatic arthritis patients who are treated with TNF inhibitors doesn’t appear to be linked to their treatment, according to a study presented EULAR this weekend.
A pilot study presented this weekend at EULAR suggests that electro stimulation of the vagus nerve reduces rheumatoid arthritis symptoms.
A 24-week trial of tildrakizumab to treat the skin and joint conditions associated with psoriatic arthritis shows promise as a possible new treatment, shows a study presented at EULAR.
An intensive treatment strategy that combines ebuxostat (Uloric, Takeda) and the novel verinurad, significantly reduced hyperuricemia and albuminuria in patients with type 2 diabetes patients.
A new study of AbbVie’s original JAK1-selective inhibitor indicates that it outdoes adalimumab without sacrificing safety in rheumatoid arthritis treatment.
Lupus nephritis remained in remission for over 10 years in a group of patients who were treated with cyclosporine A, mycophenolate mofetil or azathioprine, shows a study presented at the European Congress of Rheumatology (EULAR) annual meeting this weekend in Madrid.
Patients with rheumatoid arthritis receiving combination treatment were more likely to reach ACR20, ACR50, and ACR70 than those receiving methotrexate monotherapy.
The new study indicated that administration of a bisphosphonate before denosumab treatment, rather than at discontinuation, was far more effective at preventing rebound.
Assorted trials and a long-term exposure study of 3770 patients with rheumatoid arthritis further demonstrate baricitinib’s previously recorded safety profile.
A FUTURE 5 trial and MAXIMIZE trial demonstrate that Cosentyx frequently stops radiographic progression and lessens axial manifestations, respectively.
Ixekizumab (Talz) was significantly more likely to both reduce disease activity by ≥50% and achieve complete skin clearance than adalimumab (Humira).
We have come a long way since the introduction of glucocorticoids for the treatment of systemic lupus erythematosus (SLE). But even with improved treatment and prognosis several challenges remain in the management of SLE. Here, we highlight the 10 most important challenges in treating patients with SLE.
While rituximab has proven to be an effective treatment for rheumatoid arthritis, it has failed to meet its primary endpoints in clinical trials for systemic lupus erythematosus (SLE). But now, an observational study suggests that rituximab could be effective as maintenance therapy in difficult SLE cases.
Reactive arthritis is an inflammatory joint arthritis largely characterized by joint inflammation triggered by infection. To date, no diagnostic or classification criteria have been established, but in 2014, the American College of Rheumatology issued general treatment guidelines. In this article, we highlight a new review article on treatments for reactive arthritis.
A 40-year-old man presents to his primary care doctor complaining of pain in his ankles, knees, feet, heels, lower back and buttocks. What's your diagnosis?
Results from the phase 3 IMMhance study show that of patients who reached sPGA 0 at week 28, 73% maintained skin clearance at week 94.
A high consumption of ultra-processed foods (i.e. almost any consumable food item, except fresh fruits and vegetables) is associated with an increased risk of cardiovascular disease and mortality, show two studies in BMJ.
Patients with systemic sclerosis-associated interstitial lung disease who also take nintedanib experience a lower drop in their forced vital capacity, according to a new study.
Etanercept is a safe, well-tolerated medication for treating pediatric patients with extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis, and psoriatic arthritis, according to the results for a new study.
Switching from a biologic to a biosimilar did not affect safety or efficacy in a clinical trial of a rheumatoid arthritis biosimilar for etanercept (Enbrel, Amgen), shows a new study.
A second study published in May on the safety and efficacy of biosimilars, shows that switching rheumatoid arthritis patients from etanercept (Enbrel, Amgen) to its biosimilar etanercept-szzs (Erelzi, Sandoz), does not affect efficacy, safety or immunogenicity of etanercept.
In April, the FDA approved the etanercept biosimilar etanercept-ykro (Eticovo, Samsung Bioepis) for the same indications as its reference product Enbrel.
Despite being the most common form of inflammatory arthritis, gout continues to be poorly managed, new research indicates.
Obese patients with osteoarthritis who take metformin have a slower rate of medial cartilage loss, putting them at a reduced risk for total knee replacement, a new study found.
Racial and ethnic minority patients with lupus develop more kidney, neurological, and blood manifestations than their white counterparts, according to new research.
Despite recommendations against using opioids and benzodiazepines to treat osteoarthritis pain, new research shows significant numbers of patients, especially older patients, are still receiving prescriptions for these medications.
